Zachary K Goodman

US Patent:

20200038491, Feb 6, 2020

Filed:

Sep 28, 2017

Appl. No.:

16/337495

Inventors:

- Boston MA, US
Zachary GOODMAN - Falls Church VA, US
Barbara BURTON - Chicago IL, US
Andrew RANKIN - Branford CT, US
Mark FRIEDMAN - Newton MA, US
Paresh SONI - Mystic CT, US

International Classification:

A61K 38/46
A61K 9/00
A61P 1/16

Abstract:

The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration.